PDF-vkvrT x001BATNx001BtCx000Eq x000Brf trvTx000E frAgq vTE Cx000EvC x001B

rx000Brx000Bquisitx000Bsx001BFINACx001C5 Ix000Ftx000Brx000Fatix000Ex000Fal Busix000Fx000Bss Fix000Fax000Fx001Ex000Brx000Brx000Bquisitx000Bsx001BFINACx001Cx001D Risk Max000Fagx000Bmx000Bx000Ftvx000Ex00. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. Reducing the Risk. <Name of session> . DATE. Objectives. Define venous thromboembolism. Heighten awareness. the impact of VTE. the preventable nature of VTE. Discuss importance of . VTE risk assessment. Charles . Levenback. , MD. Professor and Deputy Chair for Patient Care. Gynecologic Oncology Center Medical Director. Lisa Kidin, RN, MSN, MHA. Sr. Business Systems Analyst. Deep vein thrombosis (DVT):. Session # 7. Venous Thromboembolism Prophylaxis. DATE. E. ducating for . Qu. ality . I. mprovement & . P. atient . S. afety. . 2. What We Are Trying to Accomplish?. OUR AIM STATEMENT. The aim of this project is to increase the compliance of ordering Venous Thromboembolism Prophylaxis for at risk 9. Updates and Clarification to the Process. This NetLearning is meant to clarify common confusion regarding the VTE Prophylaxis Process. . If you did not attend a Meaningful Use Class or take the original NetLearning, “Meaningful Use Mandatory NetLearning”, please view both to ensure that you understand the process completely!. Geoffrey Barnes, MD. Cardiovascular and Vascular Medicine. University of Michigan, USA. 1. st. Qatar Conference on . Safe Anticoagulation Management. February 27, 2015. Outline. VTE Recurrence Risk. Brandon . McMahon,. MD. Venous . Thromboembolism. (VTE). ~950,000 cases of VTE annually (incident + recurrent). Rates expected to double by 2050. Mortality. 100,000 US deaths annually. 10-30% die within a month of diagnosis. How Do Real-World Data Fit In? . Program Goals. VTE Is a Leading Cause of Death Worldwide. NOACs: VTE Clinical Trials. Real-World Data. XALIA. A Prospective, Noninterventional Study. EINSTEIN-DVT and XALIA: Outcomes. The NIMC VTE Pilot. How to use the NIMC VTE prophylaxis section. Frequently asked questions. Extent of issue. In 2008:. VTE cases 14,716. Deaths 5,285. Working age 43%. Total inpatient costs $81.2m. c  tt d )a R)qt)  radn tat&# 7KH 8QLYHUVLW\ RI ,OOLQRLV &DQFHU &HQWHU LV SDUW RI 8, +HDOWK DQG WKH 8QLYHUVLW\ RI ,OOLQRLV DW &KLFDJR 9 . *DGL 0' 3K' 'LUHFWRU 0HGLFDO 2QFRORJ\$ Objectives. Define VTE and discuss the incidence of VTE. Articulate risk factors for VTE. Discuss primary and secondary prevention. Review current guidelines. A Case…. A 12-year-old male with history of intractable epilepsy underwent right-sided craniotomy with grid placement for seizure mapping. He has a PICC line in place due to difficult IV access, and he is on bedrest. Geoffrey Barnes, MD, MSc. University of Michigan. @. GBarnesMD. May 14, 2020. Disclosures. Grants: Pfizer/Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, NHLBI, AHRQ. Consulting: Pfizer/Bristol-Myers Squibb, Janssen, Portola, AMAG Pharmaceuticals. Dr NA Smith - Haematology Dept. Heart of England NHS Foundation Trust. Venous . thromboembolism. (VTE). Venous Ulcers. . PE . DVT . Post-thrombotic. syndrome. Death. . Deep vein . insufficiency.